Antigen-based immunotherapy for autoimmune disease: current status

References

• CooperGSBynamMLSomersECRecent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseasesJ Autoimmun2009333–419720719819109
   PubMed Web of Science ®Google Scholar
• American Autoimmune Related Disease Association, Inc. c2004–2014 Available from: http://www.aarda.org/autoimmune-information/autoimmune-statistics/Accessed January 17, 2014
   Google Scholar
• LipmanTHLevitt KatzLERatcliffeSJIncreasing incidence of Type 1 diabetes in youthDiabetes Care20133661597160323340888
   PubMed Web of Science ®Google Scholar
• RosataEPisarriSSalsanoFCurrent strategies for the treatment of autoimmune diseasesJ Biol Regul Homeost Agents201024325125920846473
   PubMed Web of Science ®Google Scholar
• BernatskySHudsonMSuissaSAnti-rheumatic drug use and risk of serious infections in rheumatoid arthritisRheumatology20104671157116017478469
   PubMed Web of Science ®Google Scholar
• AtzeniFSarzi-PuttiniPBotsiosCLong-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept, and infliximab in the GISEA registryAutoimmun Rev20121222522922796281
   PubMed Web of Science ®Google Scholar
• RosmanZShoenfeldYZandman-GoddardGBiologic therapy for autoimmune diseases: an updateBMC Med2013118823557513
   PubMed Web of Science ®Google Scholar
• ThomasRDendritic cells and the promise of antigen-specific therapy in rheumatoid arthritisArthritis Res Ther20131520423374912
   PubMed Web of Science ®Google Scholar
• RoepBOPeakmannMAntigen targets of Type 1 diabetes autoimmunityCold Spring Harb Perspect Med201224a00778122474615
   PubMed Web of Science ®Google Scholar
• MirshafieyAKianiasinniMAutoantigens and autoantibodies in multiple sclerosisIran J Allergy Asthma Immunol201312429230323996705
   PubMed Web of Science ®Google Scholar
• RiemekastenGHahnBHKey autoantigens in SLERheumatology20054497598215901907
   PubMed Web of Science ®Google Scholar
• BiswasSSharmaSSarohaAIdentification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approachPLoS One201382e5624623418544
   PubMed Web of Science ®Google Scholar
• HarrisonLCWentworthJMZhangYAntigen-based vaccination and prevention of Type 1 diabetesCurr Diab Rep201313561662323888323
   PubMed Web of Science ®Google Scholar
• PeakmanMvon HerrathMAntigen-specific immunotherapy for Type 1 diabetes: maximizing the potentialDiabetes20105992087209320805382
   PubMed Web of Science ®Google Scholar
• HochfelderJLPondaPAllergen immunotherapy: routes, safety, efficacy, and mode of actionImmunotargets Ther201326171
   Google Scholar
• FujitaHSoykaMBAkdisMAkdisCAMechanisms of allergen-specific immunotherapyClin Transl Allergy20122222409879
   PubMedGoogle Scholar
• Sabatos-PeytonCAVerhagenJWraithDCAntigen-specific immunotherapy of autoimmune and allergic diseasesCurr Opin Immunol201022560961520850958
   PubMed Web of Science ®Google Scholar
• AndersonRPJabriBVaccine against autoimmune disease: antigen-specific immunotherapyCurr Opin Immunol201325341041723478068
   PubMed Web of Science ®Google Scholar
• JankovicDKuglerDGSherAIL-10 production by CD4+ effector T cells: a mechanism for self-regulationMucosal Immunol2010323924620200511
   PubMed Web of Science ®Google Scholar
• ThrowerSLJamesLPeakmanMProinsulin peptide immunotherapy in Type 1 diabetes: report of a first-in-man Phase I safety studyClin Exp Immunol2009155215616519040615
   PubMed Web of Science ®Google Scholar
• LudvigssonJFaresjöMHjorthMGAD treatment and insulin secretion in recent-onset Type 1 diabetesN Engl J Med20083591909192018843118
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Trial-Type I Study GroupEffects of oral insulin in relatives of patients with Type I diabetesDiabetes Care20052851068107615855569
   PubMed Web of Science ®Google Scholar
• KalinskiPHilkensCMUWierengaEAKapsenbergMLT-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signalImmunol Today1999201256156710562707
   PubMedGoogle Scholar
• Staeva-VieiraTPeakmanMvon HerrathMVTranslational mini-review series on Type 1 diabetes: immune-based therapeutic approaches for Type 1 diabetesClin Exp Immunol20071481173117349010
   PubMed Web of Science ®Google Scholar
• ChatneoudLImmune therapy for Type 1 diabetes mellitus – what is unique about anti-CD3 antibodies?Nat Rev Endocrinol20106314915720173776
   PubMed Web of Science ®Google Scholar
• ChaillousLLefèvreHThivoletCOral insulin administration and residual beta-cell function in recent-onset Type 1 diabetes: a multicentre randomized controlled trial. Diabete Insuline Orale GroupLancet2000356922954554910950231
   PubMed Web of Science ®Google Scholar
• PozzilliPPitoccoDVisalliNNo effect of oral insulin on residual beta-cell function in recent-onset Type 1 diabetes (the IMDIAB VII). IMDIAB GroupDiabetologia20004381000100410990077
   PubMed Web of Science ®Google Scholar
• HarrisonLCHoneymanMCSteeleCEPancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for Type 1 diabetesDiabetes Care200427102348235515451899
   PubMed Web of Science ®Google Scholar
• Näntö-SalonenKKupilaASimellSNasal insulin to prevent Type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind randomized controlled trialLancet200837296511746175518814906
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Trial – Type 1 Diabetes Study GroupEffects of insulin in relatives of patients with Type I diabetes mellitusN Engl J Med20023461685169112037147
   PubMed Web of Science ®Google Scholar
• FourlanosSPerryCHarrisonLCEvidence that nasal insulin induces immune tolerance to adults with autoimmune diabetesDiabetes20116041237124521307076
   PubMed Web of Science ®Google Scholar
• AllevaDGMakiRAPutnamALImmunomodulation in Type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B (9–23) epitopeScand J Immunol200663596916398702
   PubMed Web of Science ®Google Scholar
• WalterMPhilotheouABonniciFZieglerAGJimenezRNo effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset Type 1 diabetesDiabetes Care200932112036204019690081
   PubMed Web of Science ®Google Scholar
• AchenbachPBarkerJBonifacioEModulating the natural history of Type 1 diabetes in children at high genetic risk by mucosal insulin immunizationCurr Diab Rep200882879318445349
   PubMed Web of Science ®Google Scholar
• StaevaTPChatenoudLInselRAtkinsonMARecent lessons learned from prevention and recent-onset Type 1 diabetes immunotherapy trialsDiabetes201362191723258904
   PubMed Web of Science ®Google Scholar
• UiboRLernmarkAGAD65 autoimmunity-clinical studiesAdv Immunol2008100397819111163
   PubMed Web of Science ®Google Scholar
• WangHYangJJinLImmunotherapy of autoimmune diabetes by nasal administration of tandem glutamic acid decarboxylase 65 peptidesImmunol Invest200938869070319860582
   PubMed Web of Science ®Google Scholar
• TianJClare-SalzlerMHerschenfeldAModulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone miceNat Med1996212134813538946834
   PubMed Web of Science ®Google Scholar
• TischRLiblauRSYangXDLiblauPMcDevittHOInduction of GAD65-specific regulatory T-cells inhibits autoimmune diabetes in nonobese diabetic miceDiabetes19984768948999604865
   PubMed Web of Science ®Google Scholar
• GongZPanLLeYGluatmic acid decarboxylase epitope protects against autoimmune diabetes through activation of Th2 immune response and induction of possible regulatory mechanismVaccine201028244052405820406664
   PubMed Web of Science ®Google Scholar
• Diamyd.com (homepage on the Internet)Stockholm: Diamyd Medical AB; c2009–2013 Available from: http://www.diamyd.com/docs/trials-Diabetes.aspx?section=trialsAccessed May 21, 2014
   Google Scholar
• WherrettDKBundyBBeckerDJType 1 Diabetes TrialNet GAD Study GroupAntigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomized double-blind trialLancet2011378978831932721714999
   PubMed Web of Science ®Google Scholar
• LudvigssonJKriskyDCasasRGad65 antigen therapy in recently diagnosed Type 1 diabetes mellitusN Engl J Med2012366543344222296077
   PubMed Web of Science ®Google Scholar
• FierabracciAPeptide immunotherapies in Type 1 diabetes: lessons from animal modelsCurr Med Chem201118457758621143110
   PubMed Web of Science ®Google Scholar
• RazIZieglerAGLinnTDIA-AID 1 Writing GroupTreatment of recent-onset Type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trialDiabetes Care20143751392140024757230
   PubMed Web of Science ®Google Scholar
• LiuEMoriyamaHEisenbarthGSAnti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9–23 and B:13–23J Clin Invest200211071021102712370280
   PubMed Web of Science ®Google Scholar
• HohlfeldRWekerleHAutoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelinesProc Natl Acad Sci U S A20041012145991460615306684
   PubMed Web of Science ®Google Scholar
• PuentesFDickhautKHofstatterMFalkKRotzschkeOActive suppression induced by repetitive self-epitopes protects against EAE developmentPLoS One201385e6488823738007
   PubMed Web of Science ®Google Scholar
• MetzlerBWraithDCInhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinityInt Immunol199359115911657694644
   PubMed Web of Science ®Google Scholar
• BaiXFLiHLLinkHComplexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA ratsClin Exp Immunol199811112052109472683
   PubMed Web of Science ®Google Scholar
• WeinerHLMackinGAMatsuiMDouble-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosisScience19932595099132113247680493
   PubMed Web of Science ®Google Scholar
• WarrenKGCatzIWucherpfennigKWTolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosisJ Neurol Sci1997152131389395124
   PubMed Web of Science ®Google Scholar
• SmithCEEagarTNStromingerJLMillerSDDifferential induction of IgE-mediated anaphylaxis after soluble vs cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitisProc Natl Acad Sci U S A2005102279595960015983366
   PubMed Web of Science ®Google Scholar
• KarinNMitchellDJBrockeSLingNSteinmanLReversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha productionJ Exp Med19941806222722377525850
   PubMed Web of Science ®Google Scholar
• TurleyDMMillerSDProspects for antigen-specific tolerance based therapies for the treatment of multiple sclerosisResults Probl Cell Differ20105121723519130025
   PubMedGoogle Scholar
• BielekovaBGoodwinBRichertNEncephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligandNat Med20006101167117511017150
   PubMed Web of Science ®Google Scholar
• KapposLComiGPanitchHInduction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trialNat Med20006101176118211017151
   PubMed Web of Science ®Google Scholar
• WalczakASigerMCiachASzczepanikMSelmajKTransdermal application of myelin peptides in multiple sclerosis treatmentJAMA Neurol20137091105110923817921
   PubMed Web of Science ®Google Scholar
• JurynczykMWalczakAJurewiczAJesionek-KupnickaDSzczepanikMSelmajKImmune regulation of multiple sclerosis by transdermally applied myelin peptidesAnn Neurol201068559360121031576
   PubMed Web of Science ®Google Scholar
• AharoniRTeitelbaumDArnonRSelaMCopolymer 1 acts against the immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blockingProc Natl Acad Sci U S A19999626346399892685
   PubMed Web of Science ®Google Scholar
• SmithCEEagarTNMillerSDDifferential induction of IgE-mediated anaphylaxis after soluble vs cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitisProc Natl Acad Sci U S A2005102279595960015983366
   PubMed Web of Science ®Google Scholar
• IchimTEZhengXSuzukiMAntigen-specific therapy of rheumatoid arthritisExpert Opin Biol Ther20088219119918194075
   PubMed Web of Science ®Google Scholar
• NissimAWinyardPGCorrigallVGeneration of neoantigenic epitopes after posttranslational modification of Type II collagen by factors present within the inflamed jointArthritis Rheum200552123829383816329077
   PubMed Web of Science ®Google Scholar
• Nagler-AndersonCBoberLARobinsonMESiskindGWThorbeckeGJSuppression of Type II collagen-induced arthritis by intragastric administration of soluble Type II collagenProc Natl Acad Sci U S A19868319744374463463976
   PubMed Web of Science ®Google Scholar
• ThompsonHSHarperNBevanDJStainesNASuppression of collagen induced arthritis by oral administration of Type II collagen: changes in immune and arthritic responses mediated by active peripheral suppressionAutoimmunity19931631891998003614
   PubMed Web of Science ®Google Scholar
• YoshinoSAntigen-induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after immunizationCell Immunol1995163155587758130
   PubMed Web of Science ®Google Scholar
• KimWULeeWKRyooJWSuppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping Type II collagen: a novel treatment strategy for induction of oral toleranceArthritis Rheum20024641109112011953991
   PubMed Web of Science ®Google Scholar
• HäuselmannHJCaravattiMSeifertBCan collagen Type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trialBr J Rheumatol19983710111011179825751
   PubMedGoogle Scholar
• PrakkenBJSamodalRLeTDEpitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritisProc Natl Acad Sci U S A2004101124228423315024101
   PubMed Web of Science ®Google Scholar
• KoffemanECGenoveseMAmoxDEpitope-specific immunotherapy of rheumatoid arthritisArthritis Rheum200960113207321619877047
   PubMed Web of Science ®Google Scholar
• DominguezMDCLorenzoNBarberaAAn altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritisAutoimmunity201144647148221370936
   PubMed Web of Science ®Google Scholar
• BarberaALorenzoNGarridoGAPL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+CD25+ T cells from peripheral blood of rheumatoid arthritis patientsInt Immunopharmacol2013171075108324177275
   PubMed Web of Science ®Google Scholar
• IikuniNHahnBHLa CavaAPotential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosusExpert Opin Biol Ther20099220120619236250
   PubMed Web of Science ®Google Scholar
• MonneauxFLozanoJMPatarroyoMEBriandJPMullerST cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr miceEuro J Immunol200333287296
   PubMed Web of Science ®Google Scholar
• KaliyaperumalAMichaelsMADattaSKAntigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cellsJ Immunol19991625775578310229810
   PubMed Web of Science ®Google Scholar
• MullerSWallaceDJThe importance of implementing proper selection of excipients in lupus clinical trialsLupus2014260961424569394
   PubMed Web of Science ®Google Scholar
• MullerSMonneauxFSchallNSpliceosomal peptide P140 for immunotherapy of systemic lupus erythematosusArthritis Rheum200858123873388319035498
   PubMed Web of Science ®Google Scholar
• ImmuPharma.org (homepage on the Internet)ImmuPharma PLC 2005–2014 Available from: http://www.immupharma.org/lupuzorAccessed May 12, 2014
   Google Scholar
• SkaggsBJLourencoEVHahnBHOral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone miceLupus20112091292021562020
   PubMed Web of Science ®Google Scholar
• Tevapharm.com (homepage on the Internet) Available from: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle_Print&ID=1554647&highlight=Accessed May 12, 2014
   Google Scholar
• Tye-DinJAStewartJADromeyJAComprehensive, quantitative mapping of T cell epitopes in gluten in celiac diseaseSci Transl Med2010241ra51
   PubMed Web of Science ®Google Scholar
• Immusant.com (homepage on the Internet)ImmusanT, Incc2011 Available from: http://www.immusant.com/clinical-trial/Accessed May 12, 2014
   Google Scholar
• MartinECapiniCDugganEAntigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-KBArthritis Rheum2007562255226617599748
   PubMed Web of Science ®Google Scholar
• LoschkoJHeinkSHacklDAntigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunityJ Immunol20111876346635622079988
   PubMed Web of Science ®Google Scholar
• LookMSternEWangQANanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in miceJ Clin Invest20131231741174923454752
   PubMed Web of Science ®Google Scholar
• Raϊch-ReguéDGrau-LópezLNaranjo-GómezMStable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patientsEur J Immunol20124277178222488365
   PubMed Web of Science ®Google Scholar
• LutterottiAYousefSSputtekAInduction of immune tolerance by autologous peptide-coupled cells: a phase I trial in relapsing-remitting and secondary-progressive multiple sclerosis patientsMult Scler J201218509
   Web of Science ®Google Scholar
• Segovia-GamboaNRodríguez-ArellanoMERangel-CruzRTolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from Type 1 diabetic patientsClin Immunol20141541728324993292
   PubMed Web of Science ®Google Scholar
• ThomasRWhiteDVecchioPPhase I trial of Rheumavax to induce antigen specific tolerance in patients with rheumatoid arthritisUniversity of Queensland Available from http://www.di.uq.edu.au/clinicaltrialraAccessed May 12, 2014
   Google Scholar
• Van BrusselILeeWPRomboutsMTolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?Autoimmun Rev20141313815024120737
   PubMed Web of Science ®Google Scholar
• OrangeDEBlachereNEFakJDendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivoElife20132e0010523390586
   PubMed Web of Science ®Google Scholar
• GrossCCWiendlHDendritic cell vaccination in autoimmune diseaseCurr Opin Rheumatol20132526827423370378
   PubMed Web of Science ®Google Scholar